BioCardia (BCDA) Price & Analysis

Compare

278 Followers

BCDA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.63 - $4.66

Previous CloseN/A

Volume12.78K

Average Volume (3M)177.99K

Market Cap

$11.78M

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta2.20

Next Earnings

Aug 06, 2025

EPS Estimate

-0.5

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.59

Shares Outstanding5,503,802

10 Day Avg. Volume50,202

30 Day Avg. Volume177,993

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)0.00

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$6.00

Price Target Upside180.37% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Financial PerformanceBiocardia announced financial results with an EPS better than the analyst's estimate, indicating better-than-expected financial performance.

Financial StabilityThe company has enough cash to fund ongoing operations through the first quarter of 2025, providing financial stability in the near term.

New ProductMorph DNA Introducer now commercially available, providing new revenue stream.

Bears Say

Clinical TrialDSMB determined that the study would not meet the primary Finkelstein Schoenfeld composite endpoint and recommended to pause enrollment.

Regulatory ChallengesPMDA willing to review CardiAMP HF data ahead of submission for approval in Japan.

BioCardia News

BioCardia submits CardiAMP for consultation with Japan’s PMDA

BioCardia (BCDA) announced that it submitted its CardiAMP autologous cell therapy investigational heart failure treatment for clinical consultation...

9d ago

BCDA

Henry Ford Health initiates enrollment for BioCardia’s CardiAMP HF II study

BioCardia (BCDA) announced that Henry Ford Health in Detroit, Michigan is now enrolling patients with ischemic HFrEF in...

17d ago

BCDA

BioCardia files to sell 549K shares of common stock for holders

17:22 EDT BioCardia (BCDA) files to sell 549K shares of common stock for holders Published first on TheFly...

24d ago

BCDA

BioCardia Submits CardiAMP Therapy for PMDA Review

The latest announcement is out from BioCardia ( ($BCDA) ). On July 24, 2025, BioCardia announced the submission...

9d ago

BCDA

BioCardia Launches Phase 3 CardiAMP HF II Trial

BioCardia ( ($BCDA) ) has provided an update. On July 16, 2025, BioCardia announced that Henry Ford Health...

17d ago

BCDA

BioCardia Completes Private Placement Agreement

BioCardia ( ($BCDA) ) has issued an announcement. On June 30, 2025, BioCardia, Inc. completed a private placement...

1M ago

BCDA

BioCardia Secures Patent for Innovative Catheter System

An announcement from BioCardia ( ($BCDA) ) is now available. On June 25, 2025, BioCardia announced the granting...

1M ago

BCDA

BioCardia announces new U.S. patent for Helix Biotherapeutic delivery system

BioCardia (BCDA) announces that the United States Patent Office has granted US Patent No. 12,311,127 titled “Radial and...

1M ago

BCDA

BioCardia’s Earnings Call: Progress Amid Financial Strain

Biocardia (($BCDA)) has held its Q1 earnings call. Read on for the main highlights of the call. BioCardia’s...

3M ago

BCDA

BioCardia Reports Positive Q1 2025 Progress

Biocardia ( ($BCDA) ) has released its Q1 earnings. Here is a breakdown of the information Biocardia presented...

3M ago

BCDA

BioCardia Advances Phase 3 CardiAMP HF II Trial

BioCardia ( ($BCDA) ) has shared an update. On May 6, 2025, BioCardia, Inc. announced that the University...

3M ago

BCDA

BioCardia initiates patient enrollment at University of Wisconsin for study

BioCardia (BCDA) announced that University of Wisconsin in Madison, Wisconsin is now enrolling patients with ischemic HFrEF in...

3M ago

BCDA

BioCardia announces first patient enrolled in Phase III CardiAMP HF II trial

BioCardia (BCDA) announced the first patient enrolled in the Phase III randomized procedure placebo-controlled double-blind CardiAMP HF II...

3M ago

BCDA

BioCardia Enrolls First Patient in Phase III Trial

An announcement from BioCardia ( ($BCDA) ) is now available. On May 1, 2025, BioCardia announced the enrollment...

3M ago

BCDA

BCDA FAQ

What was BioCardia Inc’s price range in the past 12 months?

BioCardia Inc lowest stock price was $1.63 and its highest was $4.66 in the past 12 months.

What is BioCardia Inc’s market cap?

BioCardia Inc’s market cap is $11.78M.

When is BioCardia Inc’s upcoming earnings report date?

BioCardia Inc’s upcoming earnings report date is Aug 06, 2025 which is in 4 days.

How were BioCardia Inc’s earnings last quarter?

BioCardia Inc released its earnings results on May 14, 2025. The company reported -$0.59 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.59.

Is BioCardia Inc overvalued?

According to Wall Street analysts BioCardia Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does BioCardia Inc pay dividends?

BioCardia Inc does not currently pay dividends.

What is BioCardia Inc’s EPS estimate?

BioCardia Inc’s EPS estimate is -0.5.

How many shares outstanding does BioCardia Inc have?

BioCardia Inc has 5,503,802 shares outstanding.

What happened to BioCardia Inc’s price movement after its last earnings report?

BioCardia Inc reported an EPS of -$0.59 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -16.245%.

Which hedge fund is a major shareholder of BioCardia Inc?

Currently, no hedge funds are holding shares in BCDA

Company Description

BioCardia Inc

BioCardia, Inc. (BCDA) is a clinical-stage regenerative medicine company focused on the development of innovative therapeutics designed to stimulate the body's natural ability to heal itself. The company operates primarily in the biotechnology and healthcare sectors, specializing in the development of novel therapeutics for cardiovascular diseases. BioCardia's core product candidates include CardiAMP and CardiALLO cell therapies, which are intended to treat heart failure and other cardiac conditions. These therapies leverage the company's proprietary Helix biotherapeutic delivery system to deliver cells directly to the heart muscle.

BioCardia (BCDA) Earnings & Revenues

BCDA Earnings Data >

BCDA Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call highlighted significant progress in clinical trials and regulatory preparation, emphasizing the potential impact of BioCardia's therapies. However, financial challenges, including increased expenses and limited cash reserves, present ongoing challenges.Read More>

BCDA Stock 12 Month Forecast

Average Price Target

$6.00

▲(180.37%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","4":"$4","7":"$7","2.5":"$2.5","5.5":"$5.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,2.5,4,5.5,7],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Nov<br/>2024","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2,2.3076923076923075,2.6153846153846154,2.9230769230769234,3.230769230769231,3.5384615384615383,3.8461538461538463,4.153846153846154,4.461538461538462,4.769230769230769,5.076923076923077,5.384615384615385,5.6923076923076925,{"y":6,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2,2.3076923076923075,2.6153846153846154,2.9230769230769234,3.230769230769231,3.5384615384615383,3.8461538461538463,4.153846153846154,4.461538461538462,4.769230769230769,5.076923076923077,5.384615384615385,5.6923076923076925,{"y":6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2,2.3076923076923075,2.6153846153846154,2.9230769230769234,3.230769230769231,3.5384615384615383,3.8461538461538463,4.153846153846154,4.461538461538462,4.769230769230769,5.076923076923077,5.384615384615385,5.6923076923076925,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.39,"date":1696118400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.68,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.64,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.99,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.96,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.98,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.39,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.28,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.18,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.14,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.85,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.26,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >